# Hepatopulmonary Syndrome: A Student Handout for PA/Medical Students

## Learning Objectives

By the end of this session, you should be able to: 1. **Define** hepatopulmonary syndrome (HPS) and recognize its triad of diagnostic criteria 2. **Explain** the pathophysiology of intrapulmonary vascular dilatations and right-to-left shunting 3. **Recognize** the clinical presentation of orthodeoxia and platypnea 4. **Use** contrast-enhanced transthoracic echocardiography (CE-TTE) to screen for HPS 5. **Interpret** severity classification (mild, moderate, severe, very severe) based on oxygenation 6. **Understand** why HPS is an independent indication for MELD exception points 7. **Discuss** the implications of HPS + hepatorenal syndrome (HRS) for transplant candidacy and dialysis management

------------------------------------------------------------------------

## Why Nephrologists Need to Know About HPS

### You Will Encounter HPS In:

1.  **Simultaneous liver-kidney transplantation (SLKT) evaluation** — HPS may affect transplant candidacy
2.  **Dialysis patient with cirrhosis** — HPS worsens hypoxemia during volume shifts; need specialized management
3.  **Perioperative management** — Liver transplant recipients with acute kidney injury; HPS complicates anesthesia
4.  **Multidisciplinary cirrhosis care** — Hepatorenal syndrome + HPS create complex management challenges

### Prevalence

- **5-32%** of liver transplant candidates (varies by diagnostic criteria used)
- More common than initially appreciated
- Often undiagnosed until late stages
- Present in ~13% of patients with cirrhosis

------------------------------------------------------------------------

## The Diagnostic Triad of HPS

**All three components are required for diagnosis:**

### 1. Liver Disease (Portal Hypertension ± Cirrhosis)

- Any stage of liver disease with portal hypertension
- Can occur with or without cirrhosis
- Examples: Cirrhosis (any etiology), portal vein thrombosis, non-cirrhotic portal hypertension

### 2. Intrapulmonary Vascular Dilatations (IPVDs)

- **Abnormal dilation** of pulmonary precapillary and capillary vessels
- Normal vessel diameter: **8-15 μm**
- In HPS: **15-500 μm** (grossly dilated)
- **Confirmed by:**
  - **Contrast-enhanced transthoracic echocardiography (CE-TTE)** — gold standard, \>95% sensitivity
  - **99mTc-MAA (technetium-99m macroaggregated albumin) lung perfusion scan** — measures shunt fraction

### 3. Impaired Oxygenation (At Rest, Room Air)

- **Partial pressure of oxygen (PaO2) \<80 mmHg** on room air at sea level, **OR**
- **Alveolar-arterial oxygen gradient (A-a gradient) ≥15 mmHg** (≥20 mmHg if age \>64)

> **Clinical Pearl:** Do NOT rely on SpO2 alone! Pulse oximetry can be falsely reassuring. You MUST check arterial blood gas (ABG) to diagnose HPS.

------------------------------------------------------------------------

## Severity Classification

HPS is stratified by the degree of oxygenation impairment, which drives **urgency of transplantation**:

| **HPS Grade** | **PaO2 (mmHg)** | **A-a Gradient** | **Clinical Significance** |
|----|----|----|----|
| **Mild** | 80-100 | ≥15 | Minimal symptoms; observe; not transplant urgency |
| **Moderate** | 60-79 | ≥15 | Dyspnea on exertion; consider transplant; can wait weeks-months |
| **Severe** | 50-59 | ≥15 | Dyspnea at rest; transplant urgency increases; MELD exceptions given |
| **Very Severe** | \<50 | ≥15 | Profound hypoxemia; high perioperative mortality risk; complex decision-making |

### Clinical Tip

Very severe HPS (PaO2 \<50) may actually **contraindicate** complex transplantation like SLKT. The perioperative mortality risk can exceed 30%. Isolated liver transplantation is safer but still risky.

------------------------------------------------------------------------

## Pathophysiology: How Dilated Vessels Cause Hypoxemia

### The Three Mechanisms of Oxygen Impairment

#### 1. Diffusion Limitation

- Oxygen **cannot diffuse** from dilated vessel lumen to RBCs in the center of the vessel
- Normal capillaries: Small diameter allows fast diffusion
- Dilated vessels (15-500 μm): Too large; oxygen can’t reach the center of the capillary
- Result: Red blood cells transit through without picking up oxygen

#### 2. Intrapulmonary Right-to-Left Shunt

- Some blood **bypasses ventilated alveoli** entirely via dilated vessels
- Like having blood flow through a direct arteriovenous communication in the lung
- This shunted blood is **never oxygenated** regardless of supplemental O2
- Contributes to refractory hypoxemia

#### 3. Ventilation-Perfusion Mismatch

- IPVDs preferentially develop in **lung bases** (dependent zones)
- When upright, gravity increases perfusion to bases where dilated vessels predominate
- Blood preferentially flows through dilated vessels with impaired gas exchange
- Result: Mismatch between ventilation (top/bases) and perfusion (predominantly bases)

### Molecular Mechanisms Driving IPVD Formation

The liver overproduces:

| **Substance** | **Effect** | **Result** |
|----|----|----|
| **Endothelin-1 (ET-1)** | Activates ETB receptors on pulmonary endothelium | Increased NO synthesis |
| **Nitric Oxide (NO)** | Potent vasodilator | Pulmonary vasodilation, IPVD formation |
| **Carbon Monoxide (CO)** | From heme oxygenase-1 activation | Additional vasodilation |
| **VEGF** | Vascular endothelial growth factor | Angiogenesis, new abnormal vessel formation |
| **TNF-α** | From bacterial translocation | Systemic inflammation, endothelial dysfunction |

**Net Result:** Progressive, diffuse pulmonary vascular dilatation.

------------------------------------------------------------------------

## Orthodeoxia and Platypnea: The Classic Clinical Sign

### Orthodeoxia

**Definition:** Hypoxemia that **worsens in the upright position** and **improves when supine** (lying flat).

**Mechanism:** - IPVDs concentrate in lung bases - **Upright position** → Gravity increases perfusion to bases → More blood flows through dilated vessels → Greater shunting → Worse O2 uptake - **Supine position** → Gravity redistributes perfusion more evenly → Less preferential flow through basal dilated vessels → Better oxygenation

**Clinical Example:** - Seated SpO2 = 88% and dyspneic - Lying supine SpO2 = 94% and breathing easier

### Platypnea

**Definition:** Dyspnea that **worsens in upright position** and improves when lying down.

**This is orthodeoxia’s clinical companion** — the symptom that goes with the oxygenation worsening.

### Why This Matters

- **If you see orthodeoxia + platypnea in a cirrhotic patient with hypoxemia, think HPS immediately**
- This is highly specific for HPS (not seen in typical pulmonary hypertension, ILD, or ARDS)
- Ask patients: “Does your breathing feel worse when you sit up?” If yes, check ABG with patient supine vs. sitting

------------------------------------------------------------------------

## Diagnostic Workup

### Step 1: Suspect HPS in a Cirrhotic Patient With Hypoxemia

You should obtain arterial blood gas (ABG) and measure A-a gradient in any patient with: - **Cirrhosis + dyspnea** - **Portal hypertension + abnormal saturation** - **Hypoxemia that seems out of proportion** to lung findings on exam/X-ray - **Positional dyspnea** (worse upright, better supine)

### Step 2: Confirm Oxygenation Impairment

**Arterial Blood Gas (ABG):** - Measure **PaO2** and calculate **A-a gradient** = (PAO2 - PaO2) - PAO2 = (FiO2 × \[Pbaro - PH2O\]) - (PaCO2 / RQ) - At sea level, room air: PAO2 ≈ 150 - (PaCO2/0.8) - HPS diagnosed if: **PaO2 \<80 mmHg OR A-a ≥15 (≥20 if age \>64)**

### Step 3: Detect Intrapulmonary Vascular Dilatations

#### Contrast-Enhanced Transthoracic Echocardiography (CE-TTE) — Gold Standard

- **Procedure:** Agitated saline “bubble study”
  - Inject agitated normal saline intravenously
  - Microbubbles created (diameter \>10 μm) are normally **trapped in pulmonary capillaries**
  - Normally: Bubbles appear in right heart → disappear before reaching left heart
- **In HPS:** Dilated vessels allow bubbles to pass through
  - Bubbles appear in **left atrium \>3 cardiac cycles** after right heart opacification
  - **Sensitivity \>95%** for detecting IPVDs
  - Specific for right-to-left shunt

#### 99mTc-MAA Lung Perfusion Scan

- Particles (20-50 μm) normally trapped in pulmonary vascular bed
- In HPS, particles bypass lungs and accumulate elsewhere (especially brain)
- **Brain uptake \>6%** suggests significant shunting
- Can estimate **shunt fraction** quantitatively
- Less sensitive than CE-TTE but quantifies severity

### Step 4: Classify by Severity

Once HPS is confirmed, use **PaO2 or A-a gradient** to assign grade (mild/moderate/severe/very severe).

------------------------------------------------------------------------

## Clinical Presentation

### Symptoms

| **System** | **Symptoms** |
|----|----|
| **Respiratory** | Dyspnea on exertion (mild HPS) → dyspnea at rest (severe); orthodeoxia; platypnea |
| **Cardiovascular** | Palpitations (high output state); syncope (if PaO2 \<50) |
| **Neurologic** | Headache; dizziness; confusion (from hypoxemia) |
| **Constitutional** | Fatigue (chronic hypoxemia) |
| **Gastrointestinal** | Symptoms of underlying liver disease: ascites, variceal bleeding, encephalopathy |

### Physical Examination

| **Finding** | **Meaning** |
|----|----|
| **Cyanosis** (lips, fingers) | Chronic hypoxemia |
| **Digital clubbing** | Chronic hypoxemia |
| **Spider telangiectasias, palmar erythema** | Stigmata of cirrhosis |
| **Ascites, splenomegaly** | Portal hypertension |
| **Normal lung exam** | Key point! Rales/rhonchi would suggest pulmonary disease other than HPS |
| **Murmur** | Rarely present in HPS |

### Laboratory/Imaging

- **ABG:** PaO2 \<80, elevated A-a gradient
- **CXR:** Usually **normal or near-normal** — this is a vascular disease, not parenchymal
- **Pulmonary Function Tests:** Reduced DLCO (diffusing capacity), normal FEV1/FVC
- **Echo:** RV dilatation possible; RV systolic pressure normal to mildly elevated (unlike pulmonary arterial hypertension)

------------------------------------------------------------------------

## Management

### The Fundamental Reality

**Liver transplantation is the ONLY definitive treatment for HPS.** - PaO2 improvement occurs in 80-85% of transplant recipients **within 6-12 months** - No pharmacologic agent has proven consistently effective

### What Doesn’t Work (Important to Know)

Despite trials, these agents have **NOT shown sustained benefit:** - Inhaled nitric oxide - Methylene blue - Garlic - Pentoxifylline - Somatostatin - Mycophenolate

> **Teaching Point:** Don’t waste time on these. Transplant evaluation is the priority.

### Why HPS Gets MELD Exception Points

The MELD score (Model for End-Stage Liver Disease) predicts transplant urgency based on bilirubin, INR, and creatinine. But HPS patients can have **normal synthetic function** and low MELD scores yet face **high mortality from hypoxemia alone**.

**Therefore:** HPS is an **independent indication for MELD exception points** if: - **PaO2 \<60 mmHg** on room air at sea level - Documented intrapulmonary vascular dilatations - Evaluation for liver transplantation underway

This gives HPS patients **priority on transplant waiting lists** because their hypoxemia, not their liver biochemistry, drives mortality.

### Perioperative Management (Bridge to Transplant)

While waiting for transplant, manage HPS supportively:

| **Intervention** | **Rationale** |
|----|----|
| **Supplemental oxygen** | Increases inspired O2; may help some (but won’t correct shunt) |
| **Position upright as tolerated** | Improves V/Q matching in some patients |
| **Avoid volume overload** | Fluid shifts worsen V/Q mismatch |
| **Monitor closely** | Watch for decline; adjust oxygen as needed |
| **Anticoagulation if DVT risk** | Normal heparin dosing; dialysis patients need adjusted regimens |

------------------------------------------------------------------------

## HPS + Hepatorenal Syndrome: A Complex Scenario

When HPS occurs **alongside HRS**, several issues arise:

### 1. Dialysis Management Becomes Challenging

- **Volume shifts during HD** can worsen V/Q mismatch → acute hypoxemia
- Patient already hypoxic at baseline; dialysis can tip them into crisis
- **Solution:** Consider continuous modalities (CRRT, peritoneal dialysis) for more gradual solute/fluid removal

### 2. Transplant Candidacy Worsens

- **Very severe HPS (PaO2 \<50)** + **HRS** = very high perioperative risk
- Simultaneous liver-kidney transplantation (SLKT) may be too risky
- Single-organ liver transplant alone may be preferred
- Kidney function usually recovers post-liver transplant if HRS was the cause

### 3. Anesthesia Risk is Increased

- Intubation increases hypoxemia risk
- Prone positioning (some surgeries) worsens orthodeoxia
- Careful anesthesia planning with pulmonology input is essential

------------------------------------------------------------------------

## Key Clinical Pearls

1.  **Orthodeoxia + platypnea in cirrhosis = HPS until proven otherwise.** This is the clinical clue.

2.  **Don’t trust SpO2 alone.** Get an ABG. SpO2 may be 94% while PaO2 is 65 due to the way oxygen-hemoglobin curves work.

3.  **A normal CXR doesn’t rule out HPS.** The lungs look normal because IPVDs are vascular, not parenchymal. That’s a key distinguishing feature.

4.  **Mild HPS (PaO2 80-100) may progress.** Follow-up ABGs every 3-6 months; watch for decline.

5.  **Very severe HPS (PaO2 \<50) carries high surgical mortality.** Be frank with patients about transplant risks.

6.  **Liver transplant is curative.** Most patients improve significantly by 6-12 months post-transplant. This is the goal.

7.  **HPS + HRS is deadly.** Manage conservatively; prioritize for transplant urgently.

8.  **Pulmonary hypertension != HPS.** In pulmonary arterial hypertension (PAH), RV pressure is high (mean PAP \>25 mmHg); in HPS, pulmonary pressures are normal-to-low. Different diseases, different treatments.

------------------------------------------------------------------------

## Comparison Table: HPS vs. Other Causes of Hypoxemia in Cirrhosis

| **Diagnosis** | **CXR** | **DLCO** | **A-a Gradient** | **Orthodeoxia** | **CE-TTE** | **Treatment** |
|----|----|----|----|----|----|----|
| **HPS** | Normal | ↓ | ≥15 | Present | Delayed bubbles | Transplant |
| **IPH** | Infiltrates | ↓ | ↑ | Absent | Neg | Diuretics, antibiotics |
| **PAH** | Normal | ↓ | ↑ | Absent | High RV pressure | Pulmonary vasodilators |
| **Pulmonary Edema** | Infiltrates | Normal | ↑ | Absent | Normal pressures | Diuretics, vasodilators |
| **Pleural Effusion** | Effusion | May ↓ | ↑ | Absent | Normal | Treat underlying cause |

------------------------------------------------------------------------

## Practice Questions

### Question 1: Case Presentation

A 62-year-old woman with cirrhosis (Child-Pugh B) presents with progressive dyspnea over 6 months. She reports her shortness of breath is **much worse when sitting up** but improves dramatically when she lies down. Physical exam shows ascites and spider telangiectasias but **clear lungs**. CXR is normal. Resting SpO2 = 92%.

**Which test should you order next to evaluate for HPS?**

A. Pulmonary function testing (PFTs) B. Arterial blood gas (ABG) with patient both seated and supine C. High-resolution CT chest D. Right heart catheterization

**Answer:** B. This patient has classic **orthodeoxia and platypnea** (dyspnea worse upright, better supine). You must confirm the oxygenation impairment with ABG and calculate the A-a gradient. The positional nature strongly suggests HPS. ABG is the first confirmatory step. (PFTs come later; HRCT not needed; RHC would show normal pressures in HPS, not the elevated pressures of PAH.)

------------------------------------------------------------------------

### Question 2: Mechanism Question

A patient with HPS and PaO2 = 58 mmHg is given supplemental oxygen (FiO2 100% by non-rebreather). His PaO2 improves to 62 mmHg. This minimal response to high-concentration oxygen is best explained by:

A. Hypoventilation from encephalopathy B. Intrapulmonary right-to-left shunting through dilated vessels — oxygen can’t reach the shunted blood C. Pulmonary fibrosis preventing oxygen diffusion D. Anemia reducing oxygen-carrying capacity

**Answer:** B. **This is the key principle of HPS:** A true right-to-left shunt (blood bypassing ventilated alveoli) does NOT respond well to supplemental oxygen because the shunted blood is never exposed to high-oxygen air. In contrast, V/Q mismatch or hypoventilation **improves** with supplemental O2. The relative lack of response to high FiO2 is actually diagnostic of a significant shunt, which is characteristic of HPS.

------------------------------------------------------------------------

### Question 3: Management Question

A 55-year-old man with cirrhosis is found to have HPS with PaO2 = 68 mmHg and documented IPVDs on CE-TTE. He is not a transplant candidate due to advanced hepatocellular carcinoma (HCC) beyond transplant criteria. He remains short of breath despite supplemental oxygen.

**What is the most appropriate next step?**

A. Start inhaled nitric oxide therapy B. Start a pulmonary vasodilator (sildenafil) C. Refer to palliative care; optimize comfort; discuss prognosis D. Start albumin dialysis (MARS system)

**Answer:** C. This is a **prognostically difficult situation.** Without transplant as an option, pharmacologic therapies for HPS lack strong evidence and don’t alter the trajectory. The compassionate approach is **palliative care** focus: optimize symptom control (oxygen), discuss realistic prognosis (HPS without transplant carries high mortality), and ensure the patient’s values/wishes are understood. (Nitric oxide and sildenafil lack robust data; MARS is investigational.)

------------------------------------------------------------------------

## Summary: HPS at a Glance

| **Concept** | **Key Point** |
|----|----|
| **Definition** | Triad: liver disease + intrapulmonary vascular dilatations + hypoxemia |
| **Prevalence** | 5-32% of transplant candidates |
| **Pathophysiology** | IPVDs cause diffusion limitation, R→L shunt, V/Q mismatch |
| **Classic Sign** | Orthodeoxia + platypnea (dyspnea worse upright, better supine) |
| **Diagnosis** | CE-TTE (\>95% sensitivity); PaO2 \<80 OR A-a ≥15 (≥20 if age \>64) |
| **Severity** | Mild (PaO2 80-100) → Moderate (60-79) → Severe (50-59) → Very Severe (\<50) |
| **Prognosis** | Untreated: progressive decline; Transplanted: 80-85% improve in 6-12 months |
| **Treatment** | **Liver transplantation only definitive therapy**; supportive care while waiting |
| **MELD Exception** | Yes, if PaO2 \<60 mmHg; elevates transplant priority |
| **With HRS** | Complex case; SLKT vs. isolated liver transplant; increased perioperative risk |

------------------------------------------------------------------------

## References & Further Reading

1.  Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18509123/)
2.  Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100(7):1440-1452. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27326810/)
3.  Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol. 2005;39(4 Suppl 2):S138. [PubMed](https://pubmed.ncbi.nlm.nih.gov/15758649/)
4.  Goldberg DS, Krok K, Batra S, et al. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology. 2014;146(5):1256-65.e1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24412528/)
5.  European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29653741/)

------------------------------------------------------------------------

*Created for PA/Medical Student Education in Nephrology. Last updated February 2026.*

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Hepatopulmonary Syndrome](https://urinenephrology.org/mastery/hepatorenal/hepatopulmonary.html)


---

[Website version](https://urinenephrology.org/student-resources/hepatorenal/hepatopulmonary-syndrome-student-handout.html) · Markdown synchronized October 3, 2026.